The Direct Medical Costs Associated with Suspected Heparin-Induced Thrombocytopenia

被引：0
|
作者：
Natasha Nanwa
Nicole Mittmann
Sandra Knowles
Claudia Bucci
Rita Selby
Neil Shear
Scott E. Walker
William Geerts
机构：
[1] University of Toronto,Graduate Department of Pharmaceutical Sciences
[2] Sunnybrook Health Sciences Centre,HOPE Research Centre, Division of Clinical Pharmacology
[3] Sunnybrook Health Sciences Centre,Department of Pharmacy
[4] Sunnybrook Health Sciences Centre,Division of Clinical Pharmacology
[5] University of Toronto,Department of Medicine
[6] Sunnybrook Health Sciences Centre,Department of Clinical Pathology
来源：
PharmacoEconomics | 2011年 / 29卷
关键词：
Direct Medical Cost; Fondaparinux; Bivalirudin; Argatroban; Lepirudin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：511 / 520
页数：9
相关论文
共 50 条
  • [21] Rivaroxaban and apixaban for the treatment of suspected or confirmed heparin-induced thrombocytopenia
    Cirbus, Kristen
    Simone, Pamela
    Szwak, Jennifer Austin
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (01) : 112 - 118
  • [22] Characterization of hospitalized cardiovascular patients with suspected heparin-induced thrombocytopenia
    Stoll, Felicitas
    Goedde, Miriel
    Leo, Albrecht
    Katus, Hugo A.
    Mueller, Oliver J.
    CLINICAL CARDIOLOGY, 2018, 41 (12) : 1521 - 1526
  • [23] Efficacy and Safety of Fondaparinux in Patients With Suspected Heparin-Induced Thrombocytopenia
    Snodgrass, Megan N.
    Shields, Jenna
    Rai, Hema
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2016, 22 (08) : 712 - 717
  • [24] Evaluation of appropriate serologic testing for suspected heparin-induced thrombocytopenia
    Floresca, Donald
    Dupree, Lori
    Basile, Sharon
    Tan, Paul
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (18) : 1581 - 1587
  • [25] THE VALIDITY OF ALGORITHMS FOR IDENTIFYING SUSPECTED AND CONFIRMED HEPARIN-INDUCED THROMBOCYTOPENIA
    Patel, V. A.
    Walton, S. M.
    Galanter, W. L.
    Lee, T. A.
    Schumock, G.
    Nutescu, E. A.
    VALUE IN HEALTH, 2015, 18 (03) : A292 - A292
  • [26] Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study
    Linkins, L. A.
    Warkentin, T. E.
    Pai, M.
    Shivakumar, S.
    Manji, R. A.
    Wells, P. S.
    Wu, C.
    Nazi, I.
    Crowther, M. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (06) : 1206 - 1210
  • [27] PHARMACOECONOMIC ANALYSIS FOR DIAGNOSIS AND TREATMENT OF SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA
    Thomson, Julie
    To, Long
    Peters, Michael
    Kalus, James
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 256 - 256
  • [28] Comparative Analysis of the Suspected Heparin-Induced Thrombocytopenia Level in Korea
    Kim, Hun-Sung
    Kim, Hyunah
    Jeong, Yoo Jin
    Lee, Hyunyong
    Yim, Hyeon Woo
    Kim, Ji Il
    Moon, In Sung
    Kim, Jang-Yong
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 (04) : 360 - 367
  • [29] The validity of algorithms for identifying suspected and confirmed heparin-induced thrombocytopenia
    Patel, V
    Walton, S.
    Galanter, W.
    Lee, T.
    Schumock, G.
    Nutescu, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 44 - 45
  • [30] Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia
    Joseph, L.
    Casanegra, A. I.
    Dhariwal, M.
    Smith, M. A.
    Raju, M. G.
    Militello, M. A.
    Gomes, M. P.
    Gornik, H. L.
    Bartholomew, J. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (07) : 1044 - 1053
12345